Skip to main content
OpenTrials
Completed

NCT Number: NCT02447029

Self-Administered Lidocaine Gel for Pain Management With First Trimester Surgical Abortion: A Randomized Controlled Trial

Despite global efforts to decrease discomfort during surgical abortion, pain remains a limiting factor in where and how procedures are performed. Several studies have investigated different methods of delivering cervical anesthesia prior to abortion, however to the best of the investigators' knowledge, there is no published data that 1) rigorously examines the effect of a time interval between local anesthetic administration and procedure initiation, or 2) explores whether adequate pain relief is possible through self-administered, non-invasive means alone. Research in this area has a significant public health impact, given the large number of women worldwide who seek abortions.

The investigators propose to explore the effect of a locally applied vaginal lidocaine gel in place of the traditional paracervical block prior to first trimester surgical abortion. They hypothesize that lidocaine gel is no worse than paracervical block at decreasing abortion related pain at a variety of time points throughout the procedure. This is a non-inferiority, open label, randomized controlled trial.

If self-administered vaginal gel is acceptable and effective, it would increase options for pain control during abortion and other gynecologic procedures.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pregnancy, Unwanted Agnosia Nervous System Diseases Neurobehavioral Manifestations Neurologic Manifestations Pathological Conditions, Signs and Symptoms Perceptual Disorders Signs and Symptoms

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Planned Parenthood Mar Monte

San Jose, California, United States

About this study

Abortion remains one of the most common surgical procedures in the world, regardless of region or development status [Guttmacher 2012]. In the United States, at least half of all women will experience an unintended pregnancy by age 45, and one third of all women will have had an abortion by this same age [Guttmacher 2014].

Despite universal efforts to increase the comfort of these procedures, pain remains a limiting factor in where and how abortion is performed. Recent estimates reveal that 70-97% of women experience pain during abortion [Renner 2010, Paul 2009, Belanger 1988]. Strategies to reduce all aspects of abortion related pain have the potential for significant public health impact, given the large number of women who seek these services. A survey of National Abortion Federation clinics found that to date, most providers (84%) employ the use of a lidocaine paracervical block for cervical anesthesia prior to abortion [O'Connell 2009], but traditionally without a waiting period between lidocaine administration and procedure initiation.

To the best of our knowledge, there are no published studies that 1) rigorously examine the effect of a time interval between local anesthetic administration and procedure initiation, or 2) explore whether adequate pain relief is possible through self-administered, non-invasive means alone. The investigators propose to explore the effect of a locally applied lidocaine gel in place of the traditional paracervical block to decrease abortion related pain.

The objective of this study is to compare pain control at various time points during first trimester surgical abortion using a locally applied, patient-administered lidocaine gel as compared to traditional lidocaine paracervical block.

If a patient-administered vaginal gel is acceptable and effective, it would increase options for pain control during abortion and other gynecologic procedures, and perhaps replace paracervical injection altogether.

Hypothesis: Patients who receive lidocaine gel applied 30 minutes prior to first trimester surgical abortion will have pain control equivalent to that of a traditional paracervical block.

This is a non-inferiority, open-label, randomized controlled trial of women ages 18 and older undergoing first trimester surgical abortion at 50/7 to 116/7 weeks.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women ages 18 and older undergoing elective surgical abortion at 5 and 0/7 to 11 and 6/7 weeks gestational age
  • Use of IV sedation for pain management
  • English or Spanish speaking
  • Ability to give informed consent

Exclusion criteria

  • Any pre-operative use of misoprostol (typically given at 12 weeks and above in this clinic)
  • Allergy to study medications: lidocaine, midazolam, fentanyl
  • Known uterine anomaly
  • Prior cervical surgery.

Treatment and study plan

vaginal 2% Xylocaine

Drug

patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block

standard lidocaine paracervical block

Drug

1% lidocaine paracervical injection

Primary outcomes

  1. Difference in Pain Level at Time of Cervical Dilation as Measured by a Visual Analog Scale

    Time frame: At time of cervical dilation, 30 minutes after lidocaine administration

    This is the amount of pain self-reported by the patient at the time of cervical dilation. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.

Secondary outcomes

  1. Pain Level Prior to Procedure (Anticipated Pain) as Measured by a Visual Analog Scale

    Time frame: Pain level prior to procedure

    This is the amount of pain self-reported by the patient prior to the procedure (Anticipated pain). VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.

  2. Pain With Speculum Insertion as Measured by a Visual Analog Scale

    Time frame: Pain at time of speculum insertion

    This is the amount of pain self-reported by the patient at the time of speculum insertion. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.

  3. Pain With Tenaculum Placement as Measured by a Visual Analog Scale

    Time frame: Pain at time of tenaculum placement

    This is the amount of pain self-reported by the patient at the time of tenaculum placement. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.

  4. Pain 30-45 Minutes After Procedure as Measured by a Visual Analog Scale

    Time frame: Pain prior to discharge home: 30-45 minutes after completion of procedure

    This is the amount of pain self-reported by the patient 30-45 minutes after procedure. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable.

  5. Overall Satisfaction With Procedure as Measured by a Visual Analog Scale

    Time frame: 30-45 minutes after completion of procedure

    This is the level of overall satisfaction self-reported by the patient at the completion of the procedure and prior to discharge. VAS ranged from 0 to 100 mm, 0 equals not satisfied, 100 equals highest satisfaction possible.

  6. Overall Complication Rate as Measured by a Count of Participants in Each Group

    Time frame: Rate of complications at the end of the study

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Acronym: SALSA

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
May 18, 2015
Registry last updated
Feb 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.